Clinical trials in Debica

18 clinical trials in Debica, Poland across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in PolandBadaniaKliniczne.pl

Debica at a glance

clinical trials

Paediatric trials0
Research sites1

Quick filters

18 trials in Debica

Open in trial search

Cardiovascular disorder+1

Recruiting

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:Zilebesiran
Sponsor:Alnylam Pharmaceuticals Inc.

Contact Research Centre

Cardiac failure

Recruiting

Study on BI 690517 and Empagliflozin for Patients with Heart Failure and Preserved Ejection Fraction

Registered drug

Study on BI 690517 and Empagliflozin for Patients with Heart Failure and Preserved Ejection Fraction

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:BI 690517
Sponsor:Boehringer Ingelheim International GmbH

Contact Research Centre

Dyslipidaemia

Recruiting

Study of RBD5044 in Adults with Mixed Dyslipidemia to Evaluate its Safety and Effectiveness

Investigational

Study of RBD5044 in Adults with Mixed Dyslipidemia to Evaluate its Safety and Effectiveness

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:RBD5044 sodium
Sponsor:Ribocure Pharmaceuticals AB

Contact Research Centre

Obesity+1

Recruiting

Phase 3 Extension Trial Evaluating Long‑Term Efficacy, Safety and Tolerability of maridebart cafraglutide in Adults with Obesity

Investigational

Phase 3 Extension Trial Evaluating Long‑Term Efficacy, Safety and Tolerability of maridebart cafraglutide in Adults with Obesity

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:Maridebart Cafraglutide
Sponsor:Amgen Inc.

Contact Research Centre

Obesity

Recruiting

RO7795068 for Weight Loss in Adults With Obesity or Overweight and Type 2 Diabetes

Investigational

RO7795068 for Weight Loss in Adults With Obesity or Overweight and Type 2 Diabetes

Investigational

Poland

Participants:18–64 years · 65+ years
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Atrial fibrillation

Not yet recruiting

Prevention of Stroke and Systemic Embolism in Atrial Fibrillation Patients Treated with REGN7508 (cenvacibart) versus Apixaban

Registered drug

Prevention of Stroke and Systemic Embolism in Atrial Fibrillation Patients Treated with REGN7508 (cenvacibart) versus Apixaban

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Apixaban
Sponsor:Regeneron Pharmaceuticals Inc.

Contact Research Centre

Psoriatic arthropathy

Not yet recruiting

A study to evaluate the long-term safety and effectiveness of sonelokimab in patients with psoriatic arthritis

InvestigationalNo placebo

A study to evaluate the long-term safety and effectiveness of sonelokimab in patients with psoriatic arthritis

InvestigationalNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Sonelokimab
Sponsor:MoonLake Immunotherapeutics AG

Contact Research Centre

Parkinson's disease

Not yet recruiting

A study to test if BHV-8000 is effective and safe for adults with early Parkinson's disease

Registered drug

A study to test if BHV-8000 is effective and safe for adults with early Parkinson's disease

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Ioflupane (123I)
Sponsor:Biohaven Therapeutics Ltd.

Contact Research Centre

Arteriosclerosis

Not yet recruiting

Study of olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)

Investigational

Study of olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)

Investigational

Poland

Participants:18–64 years · 65+ years
Sponsor:Amgen Inc.

Contact Research Centre

Atrial fibrillation

Not yet recruiting

Stroke and Systemic Embolism Prevention with REGN7508 and REGN9933 in Adults with Atrial Fibrillation Unsuitable for Oral Anticoagulation (Phase 3)

Investigational

Stroke and Systemic Embolism Prevention with REGN7508 and REGN9933 in Adults with Atrial Fibrillation Unsuitable for Oral Anticoagulation (Phase 3)

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:REGN7508
Sponsor:Regeneron Pharmaceuticals Inc.

Contact Research Centre

Migraine

Not recruiting

Study of IncobotulinumtoxinA injections compared to placebo for prevention of episodic migraine attacks

Registered drug

Study of IncobotulinumtoxinA injections compared to placebo for prevention of episodic migraine attacks

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins
Sponsor:Merz Therapeutics GmbH

Contact Research Centre

Migraine

Not recruiting

Study of incobotulinumtoxinA injections for prevention of chronic migraine in adult patients

Registered drug

Study of incobotulinumtoxinA injections for prevention of chronic migraine in adult patients

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins
Sponsor:Merz Therapeutics GmbH

Contact Research Centre

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Debica

What the registry says about research in the country

01 Immunology & Infectious Disease Prevention

Innovative research focusing on the HPV vaccine administration in young populations, examining extended dosing regimens to prevent anogenital infections and related diseases.

HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58
Immunogenicity Studies
Pediatric Vaccination

Research explores optimal timing between vaccine doses in children aged 9-14 years compared to standard regimens in young adults.

02 Rheumatology

Clinical investigation of sonelokimab, a novel subcutaneous treatment for adults with active psoriatic arthritis who haven't previously received biological DMARDs.

Autoimmune Conditions
Joint Disease
Biologic Therapy

The research evaluates different dosing schedules to determine optimal therapeutic efficacy for inflammatory joint disease.

03 Cardiology

Groundbreaking study examining the combination of vicadrostat with empagliflozin for treating heart failure, specifically in patients with preserved ejection fraction.

Cardiovascular Disease
Combination Therapy
Heart Function

Research focuses on preventing cardiovascular death and reducing hospitalization rates in heart failure patients.

Back to Poland All countries